

Sotoca-Momblona JM¹, Rodríguez-Reyes M¹, Soy-Muner D¹


¹Pharmacy Service. Division of Medicines. Hospital Clínic de Barcelona - Universitat de Barcelona

Background and Importance

- Direct-acting antivirals (DAAs) achieve high rates of sustained virologic response in hepatitis C.
- However, studies on retreatment options for patients who have failed several DAAs treatment regimens that include nonstructural protein 5A (NS5A) inhibitors remain scarce.

Aim and Objectives

- ▶ To assess the efficacy of **glecaprevir/pibrentasvir** plus **sofosbuvir** and **ribavirin** for 12 weeks in genotype 1b patient with compensated cirrhosis who had **virologic failure to multiple treatments** including regimens containing NS5A inhibitors.





Materials and Methods

- A 50-year-old man failed multiple hepatitis C treatments.
- The resistance testing showed resistance to NS5A inhibitors except pibrentasvir.
- New treatment with **glecaprevir/pibrentasvir plus sofosbuvir and ribavirin** for 12 weeks was started.
- Prior to the treatment, drug interactions were checked.
- An undetectable HCV RNA level 12 weeks after completion of therapy (SVR12) defines treatment success.

Failed treatments	Duration
Peginterferon plus ribavirin	9 months
Sofosbuvir/ledipasvir plus ribavirin	24 weeks
Sofosbuvir/simeprevir plus ribavirin	24 weeks
Sofosbuvir/velpatasvir plus ribavirin	24 weeks

Results

- ▶ Two potential drug interactions were detected:
 - ▶ **Gemfibrozil** ⇒ it was discontinued because of increased risk of gastrointestinal side effects. 
 - ▶ **Carvedilol** ⇒ a close monitoring of heart rate and blood pressure was recommended. 
- ▶ The treatment was well tolerated and adherence was correct.
- ▶ Patient achieved SVR12 in this fifth hepatitis C treatment with glecaprevir/pibrentasvir plus sofosbuvir and ribavirin for 12 weeks.

Conclusion and Relevance

- In this particularly difficult-to-cure cirrhotic patient previously exposed to NS5A inhibitors, the combination of glecaprevir/pibrentasvir plus sofosbuvir and ribavirin administered for 12 weeks achieved SVR12.